Pierluigi Navarra

Affiliations: 
catholic University Medical School, Washington, DC, United States 
Area:
Neuroendocrinology
Google:
"Pierluigi Navarra"
Mean distance: 20.47 (cluster 31)
 
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Pozzoli G, Petrucci G, Navarra P, et al. (2019) Aspirin inhibits proliferation and promotes differentiation of neuroblastoma cells via p21 protein up-regulation and Rb1 pathway modulation. Journal of Cellular and Molecular Medicine
Lisi L, Pia Ciotti GM, Chiavari M, et al. (2019) Phospho-mTOR expression in human glioblastoma microglia-macrophage cells. Neurochemistry International. 104485
Chiavari M, Ciotti GMP, Navarra P, et al. (2019) Pro-Inflammatory Activation of A New Immortalized Human Microglia Cell Line. Brain Sciences. 9
Dello Russo C, Gagliardi D, Ramlogan R, et al. (2019) Optimizing Patient Selection to Maximize Drug Efficacy: the Expanding Role of Pharmacogenomics in the Clinical Development of Pembrolizumab for the Treatment of Non-Small Cell Lung Cancer. Clinical Therapeutics
Tringali G, Navarra P. (2019) Anti-CGRP and anti-CGRP receptor monoclonal antibodies as antimigraine agents. Potential differences in safety profile postulated on a pathophysiological basis. Peptides. 116: 16-21
Pozzoli G, Marei HE, Althani A, et al. (2019) Aspirin inhibits cancer stem cells properties and growth of glioblastoma multiforme through Rb1 pathway modulation. Journal of Cellular Physiology
Tringali G, Currò D, Navarra P. (2018) Perampanel inhibits calcitonin gene-related peptide release from rat brainstem in vitro. The Journal of Headache and Pain. 19: 107
Dello Russo C, Cappoli N, Coletta I, et al. (2018) The human microglial HMC3 cell line: where do we stand? A systematic literature review. Journal of Neuroinflammation. 15: 259
Rossetti B, Gagliardini R, Meini G, et al. (2017) Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial. Plos One. 12: e0187393
Atzori MG, Tentori L, Ruffini F, et al. (2017) The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells. Journal of Experimental & Clinical Cancer Research : Cr. 36: 106
See more...